JPS5665828A - Antitumor agent - Google Patents

Antitumor agent

Info

Publication number
JPS5665828A
JPS5665828A JP14215279A JP14215279A JPS5665828A JP S5665828 A JPS5665828 A JP S5665828A JP 14215279 A JP14215279 A JP 14215279A JP 14215279 A JP14215279 A JP 14215279A JP S5665828 A JPS5665828 A JP S5665828A
Authority
JP
Japan
Prior art keywords
agent
antibody
purity
tumor
antitumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP14215279A
Other languages
Japanese (ja)
Other versions
JPS6256136B2 (en
Inventor
Chikao Yoshikumi
Takami Fujii
Masahiko Fujii
Kenichi Matsunaga
Yoshiharu Oguchi
Koichi Niimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kureha Corp
Original Assignee
Kureha Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kureha Corp filed Critical Kureha Corp
Priority to JP14215279A priority Critical patent/JPS5665828A/en
Priority to US06/103,474 priority patent/US4315851A/en
Priority to SE7910483A priority patent/SE7910483L/en
Priority to PH23447A priority patent/PH16902A/en
Priority to GB7944494A priority patent/GB2038836B/en
Priority to CH11501/79A priority patent/CH655010A5/en
Priority to FR797932054A priority patent/FR2445149B1/en
Priority to DE2952690A priority patent/DE2952690C2/en
Priority to IT28464/79A priority patent/IT1127324B/en
Publication of JPS5665828A publication Critical patent/JPS5665828A/en
Priority to US06/321,486 priority patent/US4401592A/en
Priority to SE8406510A priority patent/SE8406510L/en
Priority to SE8406511A priority patent/SE8406511L/en
Publication of JPS6256136B2 publication Critical patent/JPS6256136B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

NEW MATERIAL:A substance obtained by subjecting a high-purity antibody to tumor antigen, prepared by purification through affinity chromatography, and an antitumor alkylating agent having at least one amino group or carboxyl group to amide bond.
EXAMPLE: An amide bond substance of a high-purity immunoglobulin induced from an antigen of human cancer, e.g., sarcoma 180, Sato's lung cancer, leukemia L-1210, Ehrlich cancer, etc. and an alkylating agent, e.g., chlorambucil, merphalan, uramustine, etc.
USE: An antitumor agent. Since the agent is bonded to a high-purity antibody to a tumor antigen, it can be transferred efficiently to tumor parts of the body, and it can exhibit antitumor effect. Normal cell, therefore, are damaged slightly and the agent has small side effects.
PROCESS: A tumor cell is injected hypodermically to an animal, which is immunized to give an antibody which is purified. The high-purity antibody and an alkylating agent are subject to amido bond.
COPYRIGHT: (C)1981,JPO&Japio
JP14215279A 1978-12-29 1979-11-02 Antitumor agent Granted JPS5665828A (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP14215279A JPS5665828A (en) 1979-11-02 1979-11-02 Antitumor agent
US06/103,474 US4315851A (en) 1978-12-29 1979-12-14 Pharmaceutical composition having antitumor activity
SE7910483A SE7910483L (en) 1978-12-29 1979-12-19 PHARMACEUTICAL COMPOSITION WITH TUMOR INHIBITION EFFECT
PH23447A PH16902A (en) 1978-12-29 1979-12-20 Pharmaceutical composition having anti-tumor activity
GB7944494A GB2038836B (en) 1978-12-29 1979-12-28 Antitumour substance
CH11501/79A CH655010A5 (en) 1978-12-29 1979-12-28 PHARMACEUTICAL ACTIVE SUBSTANCE WITH ANTITUM ORACTIVITY.
FR797932054A FR2445149B1 (en) 1978-12-29 1979-12-28 PHARMACEUTICAL COMPOSITION HAVING ANTI-TUMOR ACTIVITY
DE2952690A DE2952690C2 (en) 1978-12-29 1979-12-29 Antitumor substance, process for their preparation and pharmaceutical agent containing them
IT28464/79A IT1127324B (en) 1978-12-29 1979-12-31 Antitumour compsn. contg. high purity antibody
US06/321,486 US4401592A (en) 1978-12-29 1981-11-16 Pharmaceutical composition having antitumor activity
SE8406510A SE8406510L (en) 1978-12-29 1984-12-20 PHARMACEUTICAL COMPOSITION WITH TUMOR INHIBITION EFFECT
SE8406511A SE8406511L (en) 1978-12-29 1984-12-20 PHARMACEUTICAL COMPOSITION WITH TUMOR INHIBITION EFFECT

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14215279A JPS5665828A (en) 1979-11-02 1979-11-02 Antitumor agent

Publications (2)

Publication Number Publication Date
JPS5665828A true JPS5665828A (en) 1981-06-03
JPS6256136B2 JPS6256136B2 (en) 1987-11-24

Family

ID=15308563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP14215279A Granted JPS5665828A (en) 1978-12-29 1979-11-02 Antitumor agent

Country Status (1)

Country Link
JP (1) JPS5665828A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58118520A (en) * 1982-01-09 1983-07-14 Hidematsu Hirai Antitumor proteinic complex and preparation thereof
JPS62142123A (en) * 1983-04-08 1987-06-25 Kureha Chem Ind Co Ltd Antitumor agent bonded with human immunoglobulin

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0470125U (en) * 1990-10-25 1992-06-22

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4962194A (en) * 1972-05-10 1974-06-17
JPS5161640A (en) * 1974-09-20 1976-05-28 Searle & Co Koshuyozaino seizoho
JPS51144723A (en) * 1975-05-27 1976-12-13 Yeda Res & Dev Antiitumor agent
JPS5592325A (en) * 1978-12-29 1980-07-12 Kureha Chem Ind Co Ltd Antitumor agent and its preparation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4962194A (en) * 1972-05-10 1974-06-17
JPS5161640A (en) * 1974-09-20 1976-05-28 Searle & Co Koshuyozaino seizoho
JPS51144723A (en) * 1975-05-27 1976-12-13 Yeda Res & Dev Antiitumor agent
JPS5592325A (en) * 1978-12-29 1980-07-12 Kureha Chem Ind Co Ltd Antitumor agent and its preparation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58118520A (en) * 1982-01-09 1983-07-14 Hidematsu Hirai Antitumor proteinic complex and preparation thereof
JPS62142123A (en) * 1983-04-08 1987-06-25 Kureha Chem Ind Co Ltd Antitumor agent bonded with human immunoglobulin
JPH0653682B2 (en) * 1983-04-08 1994-07-20 呉羽化学工業株式会社 Human immunoglobulin-binding antitumor agent

Also Published As

Publication number Publication date
JPS6256136B2 (en) 1987-11-24

Similar Documents

Publication Publication Date Title
IT8223795A0 (en) GAMMA), ITS VEHICLES OF POLYPEPTIDES CONTAINING THE EXPRESSION SEQUENCE, THEIR PROCEDURE OF INTERFERON AMINO ACIDS PREPARATION, HUMAN IMMUNE COMPOSITIONS (HUMAN INTERFERON PHARMACEUTICALS CONTAINING SUCH POLYPEPTIDES.
DK0458878T3 (en) New monoclonal antibody to a new antigen associated with human tumors
EP0536275A4 (en) Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
ZA872166B (en) Synthetic htlv-iii peptides,compositions and uses thereof
DE69324487D1 (en) RECIPTOR-BINDING REGION OF THE DIPHTHERIETOXIUS
HK1012841A1 (en) Pharmaceutical composition for the treatment or prevention of amalignant tumor
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
HU9202645D0 (en) Synthetic antigenes applicables for detecting antibodies of hepatitis c virus
NZ213535A (en) Purified polyclonal antibody that binds selectively to the marker epitope encompassing amino acid position 12 of an activated form of oncogenic p21 protein
IL68201A0 (en) Peptides with the specificity of foot and mouth disease viral antigens and compositions and methods for treating animals using the same
NL191583C (en) Pre-products for essential and semi-essential amino acids in the body and method for the preparation of these pre-products.
EP0674661A4 (en) Assay and treatment for demyelinating diseases such as multiple sclerosis.
DE69126577T2 (en) Antigenic peptide for the detection of anti-hepatitis C virus antibodies and its use
JPS5665828A (en) Antitumor agent
IE852596L (en) Peptides active on the cns
ZA833483B (en) In vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
JPS5665829A (en) Antitumor agent
EP0412970A4 (en) Monoclonal antibodies against activated ras proteins with amino acid mutations at position 13 of the protein
FR2315916A2 (en) THERAPEUTIC MIXTURES INCLUDING ANALOGUES ALPHA HYDROXY ACIDS OF ESSENTIAL AMINO ACIDS AND THEIR ADMINISTRATION TO HUMANS FOR THE IMPROVEMENT OF PROTEIN SYNTHESIS AND THE SUPPRESSION OF UREA FORMATION
JPS5592325A (en) Antitumor agent and its preparation
FR2555755B1 (en) METHOD FOR DETERMINING HUMAN IMMUNOGLOBULINS WHICH ARE SPECIFIC TO HUMAN CANCER ANTIGENS AND APPLICATION OF THIS METHOD IN THE SERODIAGNOSIS OF PRIMITIVE TUMOR DISEASES
FI92716C (en) New monoclonal antibodies to IFN-Omega, their methods of preparation and their use for the purification and detection of IFN-Omega
JPS57109724A (en) Novel hapten antigen and its preparation
CA2038030A1 (en) Synthetic peptides which contain sequences from factor viia, and the use thereof
ES512769A0 (en) "PROCEDURE FOR THE PREPARATION OF 2-METOXIFENILIC ESTERS OF N-SUBSTITUTED AMINO ACIDS".